Lakewood-Amedex Biotherapeutics (LABT) Stock Analysis

What Lakewood-Amedex Biotherapeutics does

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Key metrics

ETFs linked to LABT

Broad-market and Healthcare sector ETFs an investor holding Lakewood-Amedex Biotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LABT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics trades under the ticker LABT on NASDAQ.

Which exchange is LABT listed on?

LABT is listed on NASDAQ.

What sector does Lakewood-Amedex Biotherapeutics operate in?

Lakewood-Amedex Biotherapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LABT in a portfolio?

PortView shows LABT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.